CONTEXT: Refractory acute myeloid leukemia (AML) is a difficult disease to control with second or thirdline chemotherapy regimens. In this report, we describe using azacitidine in combination with lenalidomide as salvage therapy. CASE REPORT: 52-year-old female was diagnosed with refractory AML and high-risk cytogenetics: complex monosomal karyotype consisting of t (3, 3) in association with monosomy 7 and del 5q. Morphological remission associated with maintenance of the cytogenetic abnormality of chromosome 3 and disappearance of the abnormalities relating to chromosomes 5 and 7 was achieved after three cycles of combination therapy with azacitidine and lenalidomide. CONCLUSION: Azacitidine plus lenalidomide can be a therapeutic option for patients with refractory AML, as illustrated in this case.
INTRODUCTION
Refractory acute myeloid leukemia (AML) is a difficult disease to control with conventional second or third-line chemotherapeutic regimens. Most patients die from its complications, and there is not enough time for potentially curative treatment methods such as allogenic bone marrow transplantation to be envisaged. 1 Therefore, new treatment methods need to be pursued for these patients, so as to allow their disease to be effectively controlled, thereby acting as a bridge to transplantation.
A combination of lenalidomide and azacitidine was recently described for managing AML among elderly patients. The use of these drugs was extrapolated from their action in cases of myelodysplasia. 2 Here, we describe using azacitidine in combination with lenalidomide as salvage therapy in a 52 years old AML patient with high-risk cytogenetics: complex monosomal karyotype, consisting of t (3, 3) in association with monosomy 7 and del 5q.
This patient had been refractory to a combination of Ara C and idarubicin, and to high doses of Ara C.
CASE REPORT
The patient was a 52-year-old female, who was admitted to our service (Hospital Israelita Albert Einstein, HIAE, São Paulo, Brazil) with fever and was diagnosed with acute leukemia.
On admission, she presented hemoglobin 4. On the 14th day of MIDAM, a new bone marrow aspirate showed that blast cells accounted for 70.4% of the material.
We then started her on azacitidine (75 mg/m 2 on days [1] [2] [3] [4] [5] and lenalidomide (25 mg/m 2 on days 6-19). At the end of the first cycle, she presented morphological remission (blasts in 3.6%).
Thus, two further cycles were administered, respecting the interval of 28 days, as a bridge to allogenic unrelated transplantation.
Between the second and the third cycle, there was no evidence of blast cells in the bone marrow aspirate.
She presented pleural and pericardial effusions after the first cycle, which required pericardial percutaneous drainage (Figure 1) . Pathology reports from the pericardial biopsy showed only inflammatory changes without evidence of leukemia infiltration (Figure 1) . For this reason, in the remaining two cycles, she was given lenalidomide at the reduced dosage of 25 mg/day (days 6-19) and the same dose of azacitidine was maintained.
At the end of the third cycle, she was referred for allogeneic bone marrow transplantation from an unrelated donor (10/10 HLA antigen match) with minimal residual disease (0.51% of the cells were expressing CD7, CD13, CD45 and C34). Her karyotype showed disappearance of monosomy 7 and 5q deletion, but persistence of the translocation involving chromosome 3.
The patient was conditioned using busulfan, fludarabine and thymoglobulin, and received 5 x 10 6 bone marrow cells, with bone marrow engraftment on day 12. Prophylaxis for graft-versus-host disease (GVHD) was administered, consisting of methotrexate and tacrolimus. Currently, she is doing well on the 90 th day after the procedure.
DISCUSSION
The karyotype of leukemic cells is considered to be a single vari- are grouped in the category AML-related to myelodysplasia. 1 In our case, besides a complex monosomal karyotype with myelodysplasia-related cytogenetic changes, there was involvement of a nuclear transcription factor EVE-1 (inv (3) (q21; q26. 2) or (3, 3) (q21; q26.6)). This transcription factor is related to the mechanism for proliferation and maintenance of hematopoietic cells, and aberrant expression of this factor is implicated in development and progression of high-risk AML. 1 In patients with cytogenetic findings presenting an adverse prognosis, the current recommendation is to institute consolidation therapy with allogeneic bone marrow transplantation (AloTMO)
after evaluation of the response to induction chemotherapy, which is classically performed with a combination of anthracyclines (daunorubicin or idarubicin) and cytarabine ( Table 1) . This scheme offers a complete response in 60% to 80% of young adults. 1 Lack of response to this chemotherapy, regardless of cytogenetics, confers a worse outcome. In these cases, prior to AloTMO, rescue therapy based on high-dose cytarabine is chosen in most protocols, with an overall survival of only 20 to 30%. 1 The combination of lenalidomide and azacitidine, which was proposed by Gotlib for patients older than 60 years who were diagnosed with 'new' or secondary AML, achieved a complete response rate of 44%. 2 We based our decision to start to apply this protocol in this refractory AML patient because of the similarities between her cytogenetics and those of secondary leukemias evolving from myelodysplastic syndrome (MDS), and on experience with elderly patients. [5] [6] [7] In fact, both lenalidomide and azacitidine present activity in MDS patients and in AML patients with 20-30% bone marrow blasts. [6] [7] [8] Lenalidomide is an immunomodulatory drug that is active in patients who have been diagnosed with MDS and del 5q, 6 whereas azacitidine, a hypomethylating agent, can induce hematological responses in MDS with a complex karyotype and monosomy 7.
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We observed that serous effusions were present as a complication. This was not described by Gotlib, 2 and may have resulted from the higher dose of lenalidomide, of 75 mg/day, which we used in the first cycle.
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CONCLUSION
We conclude that use of the combination of lenalidomide and azacitidine can induce morphological remission in refractory AML and that this should be further studied in larger numbers of patients after failure of conventional chemotherapy. 
